PMA device
Flair Endovascular Stent Graft
Bard Peripheral Vascular · System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV, Class III) · First FDA decision Mar 13, 2008, newest Aug 13, 2014Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
26
Naming "Flair"
MAUDE reports
218
Brand "Flair", since 2015
PubMed studies
8,845
Mentioning "Flair"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Flair Endovascular Stent Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- FLAIR ENDOVASCULAR STENT GRAFTPMA supplement
P060002-S034 · Decided Aug 13, 2014 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
- FLAIR ENDOVASCULAR STENT GRAFTPMA supplement
P060002-S027 · Decided Jan 16, 2013 · 181 days after receipt · Normal 180 Day Track
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
P060002-S002 · Decided Oct 28, 2008 · 222 days after receipt · Normal 180 Day Track
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Hemodialysis for Treatment of SchizophreniaNational determinationOn the books130.8Updated Dec 2, 2002
- Dialysis Access MaintenanceLocal determinationIn effectL34062CGS Administrators, LLCUpdated Feb 20, 2026
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
- Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower ExtremitiesLocal determinationIn effectL36377First Coast Service Options, Inc.Updated Nov 21, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Flair", any status and sponsor, newest update first.
- Cognitive Biomarkers in Pediatric Brain Tumor PatientsActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT02914067 · 154 participants · Start Oct 26, 2016 · Primary completion Nov 30, 2027
Device: rsfcMRI · For: Childhood Brain Tumor
Sites: St Louis, Missouri
- Very-Low-Field MRI for the Diagnosis of Acute StrokeNot yet recruiting
Centre Hospitalier St AnneAcademic, hospital or other
NCT07930013 · 230 participants (planned) · Start Nov 2026 · Primary completion Mar 2030
Device: Very-low-field MRI · For: Stroke
IRCCS San RaffaeleAcademic, hospital or other
NCT05907655 · 50 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 30, 2027
Device: Sleep profiler · For: Migraine
Sites: Milan, Italy
23 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Flair", and for the whole product code for context.
This brand
218 reports: 200 malfunction, 17 injury, 1 death
Whole product code PFV
2,805 reports: 1,911 malfunction, 863 injury, 31 death
Newest reports for this brand
- FLAIR ENDOVASCULAR STENT GRAFTMalfunction
BARD PERIPHERAL VASCULAR, INC.
2020394-2020-06068 · Received Oct 26, 2020
Device type: System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV)
Device problem as coded: Positioning Failure
Patient problem as coded: No Consequences Or Impact To Patient
- FLAIR ENDOVASCULAR STENT GRAFTMalfunction
BARD PERIPHERAL VASCULAR (BPV)
2020394-2020-04553 · Received Jul 16, 2020
Device type: System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV)
Device problem as coded: Break; Retraction Problem
Patient problem as coded: No Consequences Or Impact To Patient
BARD PERIPHERAL VASCULAR, INC.
2020394-2020-03506 · Received May 27, 2020 · Event dated Apr 17, 2020
Device type: System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV)
Device problem as coded: Migration or Expulsion of Device
Patient problem as coded: Injury
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0223-2016 · Started Oct 19, 2015 · Posted by FDA Nov 5, 2015
Reason given: Bard Peripheral Vascular (BPV) is recalling the Bard Flair Endovascular Stent Graft because of the harm associated with failure to deploy or deployment related issues that could occur during use.
Cause as FDA categorized it: Device Design · Device type: System, Endovascular Graft, Aortic Aneurysm Treatment (MIH)
Published research
The most relevant PubMed records for "Flair"[tiab]. The summary above synthesizes these.
- An Automatic DWI/FLAIR Mismatch Assessment of Stroke Patients.
Johansen J, Offersen CM, Carlsen JF, et al. · Diagnostics (Basel) · 2023
- FLAIR hyperintensity in the subarachnoid space: Main differentials.
Miranda Bautista J, Garrido Morro I, Fernández García P, et al. · Radiologia (Engl Ed) · 2024
- Radiomic signature of DWI-FLAIR mismatch in large vessel occlusion stroke.
Regenhardt RW, Bretzner M, Zanon Zotin MC, et al. · J Neuroimaging · 2022Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis.
Fabes J, Matthews L, Filippini N, et al. · Acad Radiol · 2017Comment
- T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor.
Onishi S, Amatya VJ, Kolakshyapati M, et al. · Eur J Radiol · 2020
- Delayed FLAIR-enhancement of benign notochordal remnant (ecchordosis physaliphora).
Peels J, Vulsteke C, Boedts M, et al. · Neuroradiol J · 2025Case Reports
- Whole-brain 3D FLAIR at 7T using direct signal control.
Beqiri A, Hoogduin H, Sbrizzi A, et al. · Magn Reson Med · 2018Research Support, Non-U.S. Gov't
- DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study.
Thomalla G, Cheng B, Ebinger M, et al. · Lancet Neurol · 2011Clinical Trial, Multicenter Study
- FLAIR2 post-processing: improving MS lesion detection in standard MS imaging protocols.
Zrzavy T, Wielandner A, Haider L, et al. · J Neurol · 2022
- T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination.
Li M, Huang W, Chen H, et al. · Front Neurol · 2022
- T1w/FLAIR ratio standardization as a myelin marker in MS patients.
Cappelle S, Pareto D, Sunaert S, et al. · Neuroimage Clin · 2022
- FLAIR Vascular Hyperintensities as a Surrogate of Collaterals in Acute Stroke: DWI Matters.
Legrand L, Le Berre A, Seners P, et al. · AJNR Am J Neuroradiol · 2023
Other devices of this type
Also filed under product code PFV.
- GORE VIABAHN Endoprosthesis with Heparin Bioactive SurfaceW. L. Gore & Associates, Inc. · PMA 2022
- Covera Vascular Covered StentC.R. Bard, Inc. · PMA 2022
- WRAPSODY® Cell-Impermeable EndoprosthesisMerit Medical Systems, Inc. · PMA 2025
- Fluency Plus Endovascular Stent GraftBard Peripheral Vascular, Inc. · PMA 2017
- Bard Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.